Company: MDCXW
Filing Date: 2025-11-19
Form Type: S-1
Source: 0001062993-25-016962
Chunk: 14

Company: Medicus Pharma Ltd.
Filing Date: 2025-11-19
Form: S-1
Chunk 14
---
 related notes included elsewhere in this prospectus

We have derived the selected condensed consolidated statements of operations for the three and nine months ended September 30, 2025 and 2024 and the selected consolidated balance sheet information as of September 30, 2025 and December 31, 2024 from our interim unaudited consolidated financial statements and audited consolidated financial statements, respectively, included elsewhere in this prospectus. Our consolidated financial statements have been prepared in accordance with GAAP and our consolidated financial statements are presented in U.S. dollars, except where indicated otherwise. Our historical results are not necessarily indicative of the results that should be expected in any future period.

<div align='center'>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</div>

| Operating expenses:                                                        | 2025 | Three months ended 
       September 30 |   | 2024 |            |   | 2025 | Nine months ended 
     September 30, |   | 2024 |            |   |
|:---------------------------------------------------------------------------|:-----|-------------------:|:--|:-----|-----------:|:--|:-----|------------------:|:--|:-----|-----------:|:--|
| General and administrative                                                 | $    |          5,024,082 |   | $    |  1,770,116 |   | $    |        12,720,666 |   | $    |  5,432,773 |   |
| Research and development                                                   |      |          1,684,783 |   |      |    564,145 |   |      |         5,130,561 |   |      |  2,162,680 |   |
| In-process research and development                                        |      |                    |   |      |            |   |      |                   |   |      |            |   |
| (IPR&D) - Teverelix                                                        |      |          8,717,475 |   |      |            |   |      |         8,717,475 |   |      |            |   |
| Total operating expenses                                                   |      |         15,426,340 |   |      |  2,334,261 |   |      |        26,568,702 |   |      |  7,595,453 |   |
| Loss from operations                                                       |      |        (15